Company Description
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men’s wellness products and services through a telemedicine platform in the United States.
The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand.
It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations.
The company markets and sells its products online through its website www.MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas.
Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
| Country | United States |
| Founded | 2021 |
| IPO Date | Mar 21, 2023 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Jacob Cohen |
Contact Details
Address: 15110 N. Dallas Parkway, Suite 600 Dallas, Texas 75248 United States | |
| Phone | 214 242 9619 |
| Website | mangoceuticals.com |
Stock Details
| Ticker Symbol | MGRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001938046 |
| CUSIP Number | 56270V106 |
| ISIN Number | US56270V1061 |
| Employer ID | 87-3841292 |
| SIC Code | 8090 |
Key Executives
| Name | Position |
|---|---|
| Jacob D. Cohen | Co-Founder, Chief Executive Officer and Chairman |
| Eugene M. Johnston | Chief Financial Officer |
| Amanda Elizabeth Hammer | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 23, 2025 | 8-K | Current Report |
| Jul 10, 2025 | 8-K | Current Report |
| Jul 3, 2025 | 8-K | Current Report |
| Jun 24, 2025 | EFFECT | Notice of Effectiveness |
| Jun 20, 2025 | UPLOAD | Filing |
| Jun 18, 2025 | EFFECT | Notice of Effectiveness |
| Jun 13, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 10, 2025 | 8-K | Current Report |
| Jun 6, 2025 | UPLOAD | Filing |
| May 30, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |